The UK and US have finalized a significant commercial pact that will guarantee zero tariffs on British drug exports going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these key exports will stay at zero for a timeframe of three years.
This development comes after recent threats to dramatically increase tariffs on patented drug products, with figures mentioned up to double the cost.
"This deal between the United Kingdom reinforces the worldwide climate for innovative medicines and brings much-needed equity to transatlantic pharmaceutical trade," a statement declared.
Trade Importance
Medicines represent one of the UK's most significant export categories to the US, which is by far the biggest destination for leading UK drugmakers.
Statistics reveal that in the one-year period to the end of September, the UK sold pharmaceutical products totaling £11.1bn to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This deal secures employment, boosts funding and sets the stage for the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The deal includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, refunds topped 20%.
Industry Background
This agreement takes place against a long-running tension between the sector and the ministers over drug pricing and regulatory access.
These tensions were heightened by claims that US patients were charged several times more for the identical medicines than people in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the past decade.
